Slingshot members are tracking this event:

FDA Approval For Allergan's CoolSculpting Treatment To Improve Appearance Of Lax Tissue In The Double Chin

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details
An 18-week clinical study of CoolSculpting in submental fat treatment found that 77 percent of patients showed improved appearance of lax tissue and 75 percent of patients reported their chin looked more toned following treatment.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 12, 2017
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Coolsculpting, Double Chin